What Is Selank? Mechanism, Structure, Evidence Tier

What is Selank? A synthetic heptapeptide derived from tuftsin, developed in Russia and studied there principally as an anxiolytic, where it is registered as a medicine. Outside that system it has no marketing authorisation from the FDA, the EMA or the MHRA, and it circulates as a research chemical.

Those two sentences describe one molecule and two entirely different objects, and almost every disagreement about this compound comes from people arguing about different ones.

What is Selank as a molecule

The description fixes two things and leaves the interesting questions open.

It is a heptapeptide, which places it in a class with predictable practical properties. Peptides are short amino acid chains, generally susceptible to enzymatic degradation and cleared quickly, which is why route and formulation matter so much for anything in this class, and why the Russian product's nasal formulation is a specification rather than a footnote. It also means the material degrades with temperature, with repeated freezing and thawing and over time in solution, so what a container holds after weeks of storage is a question rather than a given.

It is synthetic, which means the substance in any given vial is the output of a manufacturing process. Peptide synthesis produces characteristic impurities, including truncated and deletion sequences and residual reagents from the synthesis, which is why purity assays exist and why release testing distinguishes a pharmaceutical product from a powder with a label.

Tuftsin, and what a derivative inherits

The compound is described as derived from tuftsin, an endogenous peptide fragment with a described role in immune function. That relationship is often used to import claims, so it is worth stating what a derivation does and does not license.

A derivative is a different molecule. Structural modification is done precisely because it changes properties, typically stability, distribution or receptor affinity, and those changes can remove an activity as easily as they preserve one. Inheritance of a biological role from a parent structure is a hypothesis requiring test, not a property conferred by the family resemblance.

So the tuftsin connection makes certain questions sensible to ask, including immunological ones. It does not answer them, and a benefit list that carries the parent peptide's documented role across to the derivative has performed an inference and presented it as a fact.

Two regulatory identities

The answer to what is Selank depends on which regulator is asked. Registration in Russia means a national regulator reviewed a dossier covering manufacture, quality control, preclinical work and clinical data, and permitted sale for a stated indication. That is an institutional judgement made on real evidence, and it is more than any unapproved research chemical has behind it.

Absence from the Western system means something different from absence of evidence. There is no genuine registered Western trial, and no trial registry identifier should be cited for this compound. Much of the supporting literature is published in Russian in journals that are not comprehensively indexed in the databases most readers search, and the regulatory dossier is not public in a form an outside reader can examine.

The consequence is a position that has to be stated in both halves. Real clinical use and approval in one jurisdiction, and evidence that a reader outside it generally cannot inspect, which is a fact about access rather than a verdict on quality. Anyone reporting only the first is selling. Anyone reporting only the second is describing their own search results.

The search artefact that distorts this topic

A trial registry keyword search matches text anywhere in a record. Searching this compound returns nine interventional studies, and reading their titles shows what they are: an antiseizure medicine in epilepsy, transcranial stimulation for dyslexia, telephone delivered psychotherapy for depression, neurofeedback training, balance exercises. None administers this peptide to anyone.

That is why a count should never be quoted from a search field. It reports how many records contained a matching string, which is a property of a text index. The error appears in both directions: pages claiming that several trials exist have misread false matches, and pages quoting a specific number have cited a figure that refers to nothing.

Checking takes a minute. Open the record, read the official title, read the interventions field to see what is actually administered in each arm, and check whether results have been posted. Every record in this set fails at the interventions field.

The mechanistic account, and its tier

Mechanistic accounts in circulation attribute this peptide's effects to modulation of monoaminergic and GABAergic signalling and to interference with the degradation of endogenous peptides, supported by experiments in rats and in cell culture.

A mechanism is a proposed explanation. Confirming one requires showing that the pathway is engaged, that engaging it produces the effect, and that blocking it removes the effect, usually in more than one system. Even a confirmed mechanism establishes action on a pathway rather than a benefit to a person, because pathways have compensatory arms and tissue specific consequences.

The asymmetry to hold on to is that mechanistic detail is cheap and outcome data is expensive. A page can describe receptor level events at length without a single controlled human result behind any of it, and the confidence of the description carries no information about whether the outcome exists.

One further limit on the mechanistic account is worth naming, because it applies specifically to anxiolytic research. The outcome this compound is studied for is assessed with rating scales completed by participants or administered by clinicians, which converts an experience into a number through human judgement. That works inside a blinded trial and fails outside one, because expectation moves the reported value itself rather than merely its interpretation. Placebo response is large in this therapeutic area, large enough that trials are designed around it. So a mechanistic story and a subjective outcome make a combination that is unusually easy to believe and unusually hard to check, and that combination is most of what the English language internet offers about this peptide.

Numbers and structures this article does not state

Sequences, molecular weights and formulas for this compound circulate widely and are usually copied from page to page without anyone opening a primary source. None is stated here, because none has been verified against a primary record for this article.

A reader who needs those specifics should take them from a chemical database entry or a primary publication and check them there. A vendor page is a claim, not a specification, and the difference matters most precisely where the reader is least able to tell.

Where it sits in the evidence tiers

Reading the middle column top to bottom gives the shape of this compound's evidence base, and it is unlike almost any other research peptide. The top two rows are empty, the middle rows are occupied by material that exists and cannot be examined, and the bottom row is where the English language internet lives.